Marksans Pharma hits 52-week high on getting USFDA approval for Acetaminophen, Ibuprofen tablets

12 Jul 2023 , 01:29 PM

Marksans Pharma’s counter surged as much as 11% in today’s trade to touch a new 52-week high of Rs 103 after the company announced the receipt of approval from USFDA for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter (OTC) bioequivalent of Advil Dual Action Tablets 250 mg/125 mg.

At around 1.21 PM, Marksans Pharma was trading 9.63% higher at Rs 102.50, against the previous close of Rs 93.50 on NSE.

Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) are bioequivalent to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC’s reference listed drug (RLD), Advil Dual Action, which became available as an over-the-counter medication for the first time in 2020.

Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the pivotal approval, provide relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen, and acetaminophen.

Ibuprofen works through the body to target pain at its source, whereas acetaminophen blocks pain signals from reaching the brain. The breakthrough combines these two potent pain relievers into a single tablet to provide fast, effective pain relief. The company stated that the product will be available immediately.

For feedback and suggestions, write to us at [e-mail]